Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis

Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis

Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Methods Adult patients w...

Full description

Bibliographic Details
Main Authors: Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Rheumatology and Therapy
Subjects:
Guselkumab
Psoriatic arthritis
Work productivity
Health-related quality of life
Online Access:https://doi.org/10.1007/s40744-024-00642-9

Internet

https://doi.org/10.1007/s40744-024-00642-9

Similar Items